Citation Impact
Citing Papers
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases
2007 Standout
Mucosal healing in inflammatory bowel diseases: a systematic review
2012 Standout
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis
2006
Origins and evolution of the Western diet: health implications for the 21st century1,2
2005 Standout
The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene
1997 Standout
From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.
2014 Standout
Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases
2002
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
2004 Standout
MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials
2007
Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis
1998
Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial
2005
Classification and Grading of Gastritis
1996 Standout
n-3 Fatty acids for the treatment of inflammatory bowel diseases
2002
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 Standout
A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis
1994
Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis
1998
Importance of mucosal healing in ulcerative colitis
2009
Ulcerative Colitis
2011 Standout
Pro‐ and anti‐inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year
1997
Unravelling the pathogenesis of inflammatory bowel disease
2007 StandoutNature
A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis1
2002
Diet as a risk factor for the development of ulcerative colitis
2000
Pro-resolving lipid mediators are leads for resolution physiology
2014 StandoutNature
Distal Procto-Colitis, Natural Cytotoxicity, and Essential Fatty Acids
1998
Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
2011
N-3 fatty acids only delay early relapse of ulcerative colitis in remission
1996
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
2004 Standout
Crohn's disease
2012 Standout
Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis
2009
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study
2005
Legumes and soybeans: overview of their nutritional profiles and health effects
1999 Standout
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
2008 Standout
Ulcerative colitis
2002
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
1997 Standout
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
2001 Standout
Inflammatory bowel disease: cause and immunobiology
2007 Standout
A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis
1993
Inflammatory Bowel Disease
2009 Standout
Distal Proctocolitis and n-3 Polyunsaturated Fatty Acids (n-3 PUFAs): The Mucosal Effect In Situ
2000
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Essential fatty acids in health and chronic disease
1999
Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
2009
Ulcerative colitis
2012 Standout
n−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
2006 Standout
Crohn's disease
2016 Standout
Peroxynitrite-induced rat colitis—A new model of colonic inflammation
1993
Fish Intake, Contaminants, and Human Health
2006 Standout
Inflammatory Bowel Disease
2002 Standout
A Randomized, Placebo-Controlled, Phase II Study of Tetomilast in Active Ulcerative Colitis
2006
Inflammatory Bowel Disease
1991
Transcriptional control of adipocyte formation
2006 Standout
A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
1999
Medical therapy for ulcerative colitis 2004
2004
Ulcerative colitis
2016 Standout
Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter Study
2007 Standout
n−3 Fatty acid supplements in rheumatoid arthritis
2000
Inflammatory Bowel Disease
1996
Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
2010
Mechanisms of fatty acid-induced inhibition of glucose uptake.
1994 Standout
MEDICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE
1999
ESPEN Guidelines on Enteral Nutrition: Gastroenterology
2006
Eicosanoids and the gastrointestinal tract
1995
Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences
2004 Standout
Health aspects of fish and n-3 polyunsaturated fatty acids from plant and marine origin
1998
Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials
2003 Standout
Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease
2013
Inflammatory bowel disease: Etiology and pathogenesis
1998 Standout
Nutrition Support in Clinical Practice: Review of Published Data and Recommendations for Future Research Directions
1997
Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
1995 Standout
Effect of an Enteric-Coated Fish-Oil Preparation on Relapses in Crohn's Disease
1996
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
2005 Standout
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
2011
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
2006
Effects of Eradication ofHelicobacter pylorion Gastritis in Duodenal Ulcer Patients
1994
Transcriptional regulation of adipogenesis
2000 Standout
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
2004 Standout
Fat and Beyond: The Diverse Biology of PPARγ
2008 Standout
Polyunsaturated fatty acids and inflammatory bowel disease
2000
Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis
2006
Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis
1997
Inflammatory Bowel Disease
2010 Standout
Oxidative Stress: An Essential Factor in the Pathogenesis of Gastrointestinal Mucosal Diseases
2014 Standout
The PPARs: From Orphan Receptors to Drug Discovery
2000 Standout
A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn’s Disease Flares
2019 Standout
The immunological functions of the vitamin D endocrine system.
2003
Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial
2007
The Metabolic Syndrome
2008 Standout
A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis
2006 Standout
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
1999 Standout
European evidence-based Consensus on the management of ulcerative colitis: Current management
2008
Nutrition support in clinical practice: review of published data and recommendations for future research directions. Summary of a conference sponsored by the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition
1997
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
2016
The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil
1996
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer
1996 Standout
The Continuing Challenges of Leprosy
2006 Standout
Works of David Cort being referenced
Dietary Supplementation with Fish Oil in Ulcerative Colitis
1992
Oral Mesalamine (Asacol) for Mildly to Moderately Active Ulcerative Colitis
1991
Selective 5-lipoxygenase inhibition by zileuton in the treatment of relapsing ulcerative colitis
1994